MX2021014161A - Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. - Google Patents

Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.

Info

Publication number
MX2021014161A
MX2021014161A MX2021014161A MX2021014161A MX2021014161A MX 2021014161 A MX2021014161 A MX 2021014161A MX 2021014161 A MX2021014161 A MX 2021014161A MX 2021014161 A MX2021014161 A MX 2021014161A MX 2021014161 A MX2021014161 A MX 2021014161A
Authority
MX
Mexico
Prior art keywords
sjã
gren
treating
methods
syndrome
Prior art date
Application number
MX2021014161A
Other languages
English (en)
Inventor
Martin Kaul
Bruno Bieth
Buck Stefan De
Souvik Bhattacharya
Maciej Cabanski
Bruno Cenni
Arvind Kinhikar
Andrijana Radivojevic
Garami Alessandra Vitaliti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2021014161A publication Critical patent/MX2021014161A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación se relaciona con métodos para el tratamiento de la enfermedad de Síndrome de Sjögren utilizando un compuesto de Fórmula (I) o una sal farmacéuticamente aceptable del mismo. También se divulga en la presente un compuesto de Fórmula (I) o una sal farmacéuticamente aceptable del mismo, para el tratamiento de pacientes con Síndrome de Sjögren, así como también medicamentos, regímenes de dosificación, formulaciones farmacéuticas, formas de dosificación, y kits para utilizar en los usos y métodos divulgados.
MX2021014161A 2019-05-23 2020-05-20 Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. MX2021014161A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962851994P 2019-05-23 2019-05-23
PCT/IB2020/054754 WO2020234781A1 (en) 2019-05-23 2020-05-20 Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2021014161A true MX2021014161A (es) 2022-01-04

Family

ID=70918750

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014161A MX2021014161A (es) 2019-05-23 2020-05-20 Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.

Country Status (12)

Country Link
US (1) US20220175772A1 (es)
EP (2) EP4442321A2 (es)
JP (1) JP2022533968A (es)
KR (1) KR20220011652A (es)
CN (1) CN113811301A (es)
AU (1) AU2020278236A1 (es)
BR (1) BR112021023110A2 (es)
CA (1) CA3137271A1 (es)
CL (1) CL2021003034A1 (es)
IL (1) IL287745A (es)
MX (1) MX2021014161A (es)
WO (1) WO2020234781A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7443543B2 (ja) 2021-01-26 2024-03-05 ノバルティス アーゲー 医薬組成物
CA3229887A1 (en) 2021-09-03 2023-03-09 Novartis Ag Lou064 for treating multiple sclerosis
AU2022410656A1 (en) 2021-12-14 2024-06-06 Novartis Ag Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
MY197440A (en) * 2015-12-16 2023-06-19 Boehringer Ingelheim Int Heteroamatic compounds as btk inhibitors
EP3402789B1 (en) * 2016-01-13 2020-03-18 Boehringer Ingelheim International Gmbh Isoquinolones as btk inhibitors
AR113796A1 (es) * 2017-11-06 2020-06-10 Lilly Co Eli Compuestos inhibidores de tirosina cinasa de bruton (btk)

Also Published As

Publication number Publication date
BR112021023110A2 (pt) 2022-04-12
CA3137271A1 (en) 2020-11-26
AU2020278236A1 (en) 2022-01-06
CL2021003034A1 (es) 2022-09-09
EP4442321A2 (en) 2024-10-09
WO2020234781A1 (en) 2020-11-26
CN113811301A (zh) 2021-12-17
AU2020278236A8 (en) 2022-04-28
EP3972603B1 (en) 2024-09-04
US20220175772A1 (en) 2022-06-09
JP2022533968A (ja) 2022-07-27
TW202110451A (zh) 2021-03-16
KR20220011652A (ko) 2022-01-28
IL287745A (en) 2021-12-01
EP3972603A1 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
MX2021014161A (es) Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
PH12019500025A1 (en) Cancer treatment combinations
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
MX2021013942A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton.
PH12019502334A1 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
ATE485037T1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2021014774A (es) Formulaciones de liberacion modificada y usos de las mismas.
PH12021551371A1 (en) Pharmaceutical composition for the treatment of pulmonary arterial hypertension
GB2590189A9 (en) Lycorine derivatives, pharmaceutical composite thereof and usage therefor
CO2022008730A2 (es) Composición farmacéutica para el tratamiento de la enfermedad vascular pulmonar y/o disfunción cardíaca en pacientes paliados con fontan
RU2013149635A (ru) Соединения солифенацина и слюнные стимулянты для лечения гиперактивности мочевого пузыря
NO20024683D0 (no) Terapier med oppdelte doser som har vaskul¶rt skadende aktivitet
WO2021133894A8 (en) Btk inhibitors
BR112022009716A2 (pt) Dosagem de um inibidor de tirosina quinase de bruton
PL425832A1 (pl) Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera
MX2021008303A (es) Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa.
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
MX2024008626A (es) Antagonista de tlr7/8 para el tratamiento del sindrome de sjogren o la enfermedad mixta del tejido conectivo.
MX2023013650A (es) Compuesto usado como inhibidor de bcr abl.